MicroRNA-21 is Required for Hematopoietic Cell Viability After Radiation Exposure
Creators
- 1. Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville (United States)
- 2. Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia (United States)
- 3. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas (United States)
- 4. Department of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia (United States)
Description
Radiation therapy is an essential intervention used in the treatment of more than half of cancer patients. With the increasing use of hypofractionated radiation regimens, concurrent use of radiation and chemotherapy, targeted agents and immunotherapy, the risk of radiation-induced toxicities is increased. However, much remains unknown about the molecular underpinnings responsible for radiation-induced toxicity. MicroRNA (miRNA) are small, non-coding RNA involved in post-transcriptional regulation of gene expression. miR-21 is an oncomiR that is dysregulated in a significant fraction of human malignancies, and its overexpression is linked to poor overall survival, chemoresistance, and radioresistance in several human cancers. However, the contribution of miR-21 in governing radiation sensitivity in normal, untransformed cells, and the impact of silencing this miRNA in normal tissues remains largely unexplored.
Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2019.04.020;
- PII
- S0360301619306522;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 104
- Journal Issue
- 5
- Journal Page Range
- p. 1165-1174
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55057350
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANIMAL TISSUES; CHEMOTHERAPY; HEALTH HAZARDS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PATIENTS; RADIOSENSITIVITY; RADIOTHERAPY; RNA; TOXICITY; VIABILITY
- Descriptors DEC
- ANIMALS; BODY; DISEASES; HAZARDS; MAMMALS; MEDICINE; NUCLEAR MEDICINE; NUCLEIC ACIDS; ORGANIC COMPOUNDS; PRIMATES; RADIOLOGY; SENSITIVITY; THERAPY; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2019 Published by Elsevier Inc.